The estimated Net Worth of Jonathan B. Siegel is at least $1.48 Tisíc dollars as of 17 May 2023. Mr. Siegel owns over 1,145 units of Jaguar Health Inc stock worth over $1,476 and over the last 6 years he sold JAGX stock worth over $0. In addition, he makes $0 as Independent Director at Jaguar Health Inc.
Sign up
Mr. Siegel JAGX stock SEC Form 4 insiders trading
Jonathan has made over 6 trades of the Jaguar Health Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,145 units of JAGX stock worth $1,294 on 17 May 2023.
The largest trade he's ever made was buying 25,000 units of Jaguar Health Inc stock on 4 October 2018 worth over $15,000. On average, Jonathan trades about 5,974 units every 161 days since 2018. As of 17 May 2023 he still owns at least 1,306 units of Jaguar Health Inc stock.
You can see the complete history of Mr. Siegel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Siegel biography
Jonathan B. Siegel serves as Independent Director of the Company. Mr. Siegel is founder of JBS Healthcare Ventures, which pursues investments in public and private healthcare entities. He also serves as a member of the board of Sol-Gel Technologies, Ltd, a Nasdaq-listed company since 2018. In 2017 he left Kingdon Capital, where he was a principal of the firm, a member of the executive committee and the sector head for healthcare. He joined Kingdon in 2011 and has more than 20 years of investment experience. Prior to joining Kingdon, Mr. Siegel was with SAC Capital Advisors from 2005 to 2011, serving as a portfolio manager for healthcare starting in 2007. Before joining SAC, he was an associate director of pharmaceutical and specialty pharmaceutical research with Bear, Stearns & Co., a research associate with Dresdner Kleinwort Wasserstein, specializing in pharmaceuticals, a consultant to the Life Sciences Division of Computer Sciences Corporation; a research associate at the Novartis Center for Immunobiology, Harvard Medical School, Beth Israel Deaconess Medical Center, and a research assistant at Tufts University School of Medicine. Additionally, he previously served on the board of KV Pharmaceutical Company. Mr. Siegel received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999. Mr. Siegel is qualified to serve on our board of directors due to his extensive experience in the pharmaceutical investment sector.
How old is Jonathan Siegel?
Jonathan Siegel is 46, he's been the Independent Director of Jaguar Health Inc since 2018. There are 13 older and 1 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
What's Jonathan Siegel's mailing address?
Jonathan's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Insiders trading at Jaguar Health Inc
Over the last 10 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski a Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
What does Jaguar Health Inc do?
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
What does Jaguar Health Inc's logo look like?
Complete history of Mr. Siegel stock trades at Jaguar Health Inc
Jaguar Health Inc executives and stock owners
Jaguar Health Inc executives and other stock owners filed with the SEC include:
-
Lisa Conte,
President, Chief Executive Officer, Director -
Steven King,
Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary -
Lisa A. Conte,
Founder, CEO, Pres & Director -
Jonathan Wolin,
Chief of Staff, General Counsel and Chief Compliance Officer -
Jonathan S. Wolin CPA, J.D., M.B.A.,
Chief of Staff, Chief Compliance Officer & Gen. Counsel -
Dr. Steven R. King,
Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. -
James Bochnowski,
Independent Chairman of the Board -
Jonathan Siegel,
Independent Director -
Jiahao Qiu,
Independent Director -
John Micek,
Independent Director -
Gregory Divis,
Independent Director -
Melissa Yeager,
Senior Vice President - Regulatory Affairs & Quality Assurance -
Carol Lizak,
Senior Vice President - Finance, Chief Accounting Officer -
Melissa A. Yeager J.D.,
Sr. VP of Regulatory Affairs & Quality Assurance -
Ian H. Wendt M.B.A.,
Chief Commercial Officer -
David Sesin,
Chief Manufacturing Officer -
Dr. Karen Brunke Ph.D.,
Exec. VP of Corp. & Bus. Devel. -
Peter Hodge,
Sr. Director of Investor Relations, Bus. Devel. & Special Events -
Dr. Pravin R. Chaturvedi Ph.D.,
Chair of Scientific Advisory Board & Acting Chief Scientific Officer -
Carol R. Lizak,
Chief Financial Officer -
Roger J. Waltzman,
Chief Scientific Officer -
Folkert W. Kamphuis,
Director -
Philippe Brianceau,
Chief Veterinary Officer -
Murray David Mac Naughtan,
-
Zhi Yang,
Director -
Ari Azhir,
Director -
Karen Steil Wright,
CFO and Treasurer -
Jeffery C. Johnson,
-
Jonathan M Glaser,
-
Bryan Bryan Ezralow 1994 Tr...,
-
Investments Ltd Burford Cap...,
-
Capital Partners, L.P.Sagar...,
-
John A Kallassy,
CFO, COO, Treasurer -
Management, Ltd.Kunlun Phar...,
-
Michael Hauser,
Chf Veterinarian, Clinical Ops -
Anula Jayasuriya,
Director -
Pravin R Chaturvedi,
Chief Scientific Officer